Jeremy P. Segal, MD, PhD

Director, Genomic and Molecular Pathology

Associate Professor of Pathology University of Chicago, United States

Biography:

Jeremy Segal, is an Associate Professor of Pathology and the Director of the Division of Genomic and Molecular Pathology at The University of Chicago. Dr. Segal received an MD from Weill Cornell Medical College and a PhD in Genetics from Rockefeller University, and completed Anatomic Pathology training at New York Hospital – Weill Cornell and Molecular Genetic Pathology training at the Hospital of the University of Pennsylvania. After training, he worked at the New York Genome Center as Director of Clinical Development and Policy before joining the faculty at the University of Chicago. Dr. Segal specializes in genomics technol- ogies and bioinformatics, and has been chiefly responsible for the development of the Division of Genomic and Molecular Pathology, including creation of the Clinical Genomics Laboratory and development/validation of its oncology testing assays. Test platforms in service at UChicago include large-scale DNA and RNA sequenc- ing systems to support personalized cancer care and clinical trial recruitment. Dr. Segal’s research interests revolve around novel use of genomics technologies to improve diagnostics and drive biomarker development, with current areas of inter- est including minimal residual disease assays and emerging epigenetics applications.

Roland Schwarting, MD

Department of Pathology at Cooper University Health Care Professor of Pathology

Chairman and Chief, Departments of Pathology Cooper University Health Care

President, Cooper Medical Staff

Cooper Medical School of Rowan University, United States

Biography:

Dr. Roland Schwarting, is the Chairman of Pathology and Laboratory Medicine at Cooper University Hospital, and Professor of Pathology at CMSRU. Dr. Schwarting subsequently spent three years at Sloan-Kettering Cancer Center developing tumor markers some of which have US patents and are distributed worldwide. He is President Elect of the Medical Staff of the Cooper Health System, and serves also as the President of the South Jersey Pathology Society. Dr. Schwarting serves as Trustee of Cooper University Hospital. He serves as a Member of Board of Trustees of Cooper University Health Care. Dr. Schwarting finished his residency in pathology in Berlin Germany, and continued as an attending pathologist at Thomas Jefferson University until 2006. He is board-certified in Anatomic and Clini- cal Pathology and Hematopathology. He received his M.D. degree from Kiel University, Germany, in 1981.

Special Interests

Hematopathology, flow cytometry, lymphoma

William D Travis, MD, FCCP

Attending Thoracic Pathologist

Director, Thoracic Pathology and Director of the Thoracic Pathology Training Program

Memorial Sloan Kettering Cancer Center, United States

Biography:

Dr. Travis is the Director of Thoracic Pathology and the Thoracic Pathology Train- ing Program at Memorial Sloan Kettering Cancer Center, New York. He graduated from Haverford College and the University of Florida College of Medicine, Gaines- ville. He completed an Anatomic Pathology residency at Harvard Medical School, Boston at the New England Deaconess Hospital, as well as a Clinical Pathology residency and surgical pathology fellowship at Mayo Clinic, Rochester, Minnesota. Dr. Travis is an Honorary Pulmonary Fellow from the Mayo Clinic Departments of Thoracic Medicine and Surgery and received the Mary J. Matthews Award for Excellence in Research of Lung Cancer Pathology from the International Associa- tion for the Study of Lung Cancer. He served as Chair of the 1999 WHO Classifica- tion of Lung and Pleural Tumors, as well as lead editor of the 2004 and 2015 WHO Classifications: Pathology and Genetics of Tumors of the Lung, Pleura, Thymus and Heart and will serve as an expert member of the WHO Blue Books 5th Edition Editorial Board for the upcoming Thoracic Tumors volume. Dr. Travis served as co-chair of the 2002 American Thoracic Society (ATS) and European Respiratory Society (ERS) International Multidisciplinary Consensus Classification of Idiopathic Interstitial Pneumonias (IIPs), co-chair of the 2008 ATS Workshop on Nonspecific Interstitial Pneumonia. He helped co-chair the 2011 IASLC/ATS/ERS International Multidisciplinary Classification of Lung Adenocarcinoma, and co-chair of the 2013 ATS/ERS Update of the International Multidisciplinary Consensus Classification of IIPs. He has been the director of a Thoracic Pathology Fellowship training program for 29 years.

Daniel J Brat, MD, PhD

Chair, Department of Pathology

Magerstadt Professor of Pathology Professor of Pathology

Feinberg School of Medicine, Northwestern University, United States

Biography:

Dr. Brat received his MD and PhD from the Mayo Medical and Graduate Schools and then completed Residency in Anatomic Pathology and a Fellowship in Neuro- pathology at Johns Hopkins Hospital. He joined the Department of Pathology and Laboratory Medicine at Emory University in 1999, spending 17 years on faculty before accepting the position of Magerstadt Professor and Chair of Pathology at the Northwestern University Feinberg School of Medicine and Pathologist-in-Chief of Northwestern Memorial Hospital. Dr. Brat directs a basic and translational research lab that investigates mechanisms of glioma progression, including the contributions of hypoxia, genetics, tumor microenvironment and stem cells.

Glioma progression is characterized by tumor necrosis, severe hypoxia and angio- genesis. One project investigates mechanisms that cause hypoxia and has focused on vaso-occlusion and intravascular thrombosis that are thought to be initiated by tissue factor, a highly potent pro-coagulant. His lab is studying how the resulting altered micro-environment leads to accelerated tumor growth how the enrichment of glioma stem cells and influx of tumor associated macrophages may promote this.

Pancras C.W. Hogendoorn, MD, PhD

Professor of Pathology

Vice Chairman of the Board, Dean

Leiden University Medical Center, the Netherlands

Biography:

Pancras C.W. Hogendoorn is a professor of pathology, a member of the Board of Directors, and the dean of the Leiden University Medical Center (LUMC). Apart from that he is a guest professor at Oxford University and the Free University of Brussels (FUB). He is also chairman of the Netherlands Committee for Bone Tumours, a member of the Supervisory Board of the care organisation Pieter van Foreest, the National Museum Boerhaave, and the Royal Academy of Arts. Pancras C.W. Hogendoorn absolved Medical School and his doctoral research at Leiden University. The title of his doctoral thesis (1990) reads ‘Immunopathogenet- ic mechanisms in experimental glomerulonephritis’. Subsequently Prof. Hogen- doorn further specialized in oncologic pathology at the Netherlands Cancer Institute (NKI) in Amsterdam and the Memorial Sloan Kettering Cancer Center in New York. In March 1999 he was appointed Professor in Pathology of the Leiden University Medical Center. The title of his inaugural lecture was ‘Form Follows Function’. For more than 25 years, Prof. Hogendoorn has carried out research into molecular pathogenesis and diagnostics of bone and soft-tissue tumours. He has over 400 scientific publications and various influential reviews and 23 chapters of books to his name. Prof. Hogendoorn has held a number of national and interna- tional offices at scientific organizations. Currently he is chairman of the Nether- lands Committee for Bone Tumours, a member of the knowledge coalition for the Dutch National Research Agenda, chairman of the Bone and Soft Tissue working group European Society of Pathology, chairman of Education and Training (O&O) at the Netherlands Federation of University Medical Centres (NFU), and chairman of the League of European Research Universities (LERU) Policy Group in Biomedicine. In the past he was, among other things, chairman of the sub-committee of Pathology and Biology of the EORTC Soft tissue and Bone Sarcoma Group, the European Osteosarcoma Intergroup, the EuroEwing consortium, chairman of Eurolife, and a board member of the Connective Tissue Oncology Society and the European Musculoskeletal Oncology Society. Prof. Hogen- doorn was a member of the advisory board of the prestigious Journal of Pathology. He held the same post for Diagnostic Histopathology and Hereditary Cancer in Clinical Practice. Prof. Hogendoorn is still an active member of the working group of bone and soft-tissue tumours of the European Society for Pathology and the United States Academy of Pathology. Because of his research and diagnostic work in the field of bone and soft-tissue tumours, the World Health Organisation (WHO) asked him in 2002 to join the working group for the classification of these tumours. As such he was a co-author of the WHO classification for bone and soft-tissue tumours and was in 2013 appointed editor of the most recent edition.

Xiu-Wu Bian, MD and PhD

Chairman, the 11th Asia Pacific IAP Congress Professor of pathology

Academician of Chinese Academy of Sciences

President, Chinese Division of the International Academy of Pathology (CDIAP)

President, Chinese Association of Pathologists (CAP), Chinese Medical Doctor Association (CMDA)

Biography:

Xiu-Wu Bian is member of Chinese Academy of Sciences. He is the director of the Institute of Pathology and Southwest Cancer Center, Southwest Hospital, Third Military Medical University. He is the President of Chinese Division of International Academy of Pathology (CDIAP), the Immediate Past President of Chinese Society of Pathology (CSP), the Chairman of Chinese Association of Pathologists (CAP) and the President-elect of Tumor Metastasis Research Committee of Chinese Anti-cancer Association (CACA). His research interests include cancer stem cells and tumor microenvironment. Dr. Bian has practiced pathological diagnosis for 30 years and is experienced in brain tumor pathology. He has published more than 300 papers in peer-reviewed journals including Nature, Nat Immunol, Cell Stem Cell, Sci Transl Med, Nat Commun, PNAS, JNCI, etc.